Back to search

Peptide record

TPDB65713

iRGD Tumor-homing Peptides standard
9 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB65713
iRGD
Tumor-homing Peptides
Cancer-related peptides
TumorHoPe2.0
standard
No
A 9-aa standard natural tumor-homing peptides peptide sequence curated from TumorHoPe2.0, with an available 3D structural model.
Sequence
CRGDKPGDC
Physicochemical Analysis
C35H59N13O14S2
ANEQHILMFSTWYV
DCG
950.05
6.09
2
2
0
-0
4.25
-1.422
0.00
Mammalian: 1.2 hour Yeast: >20 hour E.coli: >10 hour
125
13.16
2
Residue Composition
number
0
A
1
R
0
N
2
D
2
C
0
E
0
Q
2
G
0
H
0
I
0
L
1
K
0
M
0
F
1
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 1 N: 0 D: 2 C: 2 E: 0 Q: 0 G: 2 H: 0 I: 0 L: 0 K: 1 M: 0 F: 0 P: 1 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
9
C35H59N13O14S2
950.05
6.09
-0
4.25
-1.422
RGD
Evidence Records 9 records
Evidence 1 Activity

Activity

Tumor-homing Peptides

Target

Tumor cell, Tumor vessel
Homing
Glioblastoma

Source & Reference

TumorHoPe2.0
TumorHoPe2
The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells
2013
Guangzhi Gu et al. Biomaterials. 2013 Jul 34(21):5138-48.

Other

Source Activity Label Source Definition
Tumor-homing Peptides
TumorHoPe2.0 experimentally validated tumor-homing peptide annotation.
C6 glioma cells
paclitaxel, PEG-PLA nanoparticles (MT1-NP-PTX)
Evidence 2 Activity

Activity

Tumor-homing Peptides

Target

Tumor cell
Homing

Source & Reference

TumorHoPe2.0
TumorHoPe2
Doxorubicin delivery to 3D multicellular spheroids and tumors based on boronic acid-rich chitosan nanoparticles
2013
Xin Wang et al. Biomaterials. 2013 Jun 34(19):4667-79.

Other

Synthetic
Boronic acid-rich chitosan-poly(N-3-acrylamidophenylboronic acid) nanoparticles, doxorubicin
Evidence 3 Activity

Activity

Tumor-homing Peptides

Target

Tumor cell
Homing
Melanoma

Source & Reference

TumorHoPe2.0
TumorHoPe2
[Cellular toxicity and anti-tumor efficacy of iRGD modified doxorubixin loaded sterically stabilized liposomes]
2013
Bo Zhao et al. Yao Xue Xue Bao. 2013 Mar 48(3):417-22.

Other

B16 melanoma cell line
C57BL/6 mice
Synthetic
doxorubicin
Evidence 4 Activity

Activity

Tumor-homing Peptides

Target

Tumor cell
Homing
NRP-1

Source & Reference

TumorHoPe2.0
TumorHoPe2
Enhanced therapeutic efficacy of iRGD-conjugated crosslinked multilayer liposomes for drug delivery
2013
Yarong Liu et al. Biomed Res Int. 2013:2013:378380.

Other

4T1 tumor cells, JC cells
Female 6- to 10-week-old BALB/c mice
Synthetic
cMLVs
Evidence 5 Activity

Activity

Tumor-homing Peptides

Target

Homing
Glioma

Source & Reference

TumorHoPe2.0
TumorHoPe2
2016
Chang Liu et al. J Drug Target. 2017 Mar 25(3):235-246.

Other

poly (lactide-co-glycolides) nanoparticles, carmustine (BCNU)
Evidence 6 Activity

Activity

Tumor-homing Peptides

Target

Homing

Source & Reference

TumorHoPe2.0
TumorHoPe2
2016
Fei Yan et al. J Control Release. 2016 Feb 28:224:217-228.

Other

indocyanine green (ICG) liposomes
Evidence 7 Activity

Activity

Tumor-homing Peptides

Target

Tumor cell
Homing
Breast cancer

Source & Reference

TumorHoPe2.0
TumorHoPe2
Dual-targeting exosomes for improved drug delivery in breast cancer
2023
Nam Hb Tran et al. Nanomedicine (Lond). 2023 Mar 18(7):599-611.

Other

MCF-7and MDA-MB-231 breast cancer cell line
Phage Display Library
doxorubicin (Dox)
Evidence 8 Activity

Activity

Tumor-homing Peptides

Target

Tumor cell
Homing
Colon cancer
αvβ6

Source & Reference

TumorHoPe2.0
TumorHoPe2
Tumor-homing peptide iRGD-conjugate enhances tumor accumulation of camptothecin for colon cancer therapy
2024
Tejinder Singh et al. Eur J Med Chem. 2024 Feb 5:265:116050.

Other

Synthetic
camptothecin
Evidence 9 Activity

Activity

Tumor-homing Peptides

Target

Tumor cell
Homing
Breast cancer

Source & Reference

TumorHoPe2.0
TumorHoPe2
Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer
2023
Shipeng He et al. J Med Chem. 2023 Dec 28 66(24):16828-16842.

Other

Proteolysis-targeting chimeras (PROTACs)
Additional Detail Fields 3 fields
paclitaxel, PEG-PLA nanoparticles (MT1-NP-PTX) Boronic acid-rich chitosan-poly(N-3-acrylamidophenylboronic acid) nanoparticles, doxorubicin doxorubicin cMLVs poly (lactide-co-glycolides) nanoparticles, carmustine (BCNU) indocyanine green (ICG) liposomes doxorubicin (Dox) camptothecin Proteolysis-targeting chimeras (PROTACs)
C6 glioma cells B16 melanoma cell line 4T1 tumor cells, JC cells MCF-7and MDA-MB-231 breast cancer cell line
C57BL/6 mice Female 6- to 10-week-old BALB/c mice